Crossject Société Anonyme (EPA:ALCJ)
France
· Delayed Price · Currency is EUR 2.000
-0.030 (-1.48%)
Mar 9, 2026, 5:35 PM CET
Crossject Société Anonyme Revenue
Crossject Société Anonyme had revenue of 1.54M EUR in the half year ending June 30, 2025, a decrease of -50.29%. This brings the company's revenue in the last twelve months to 4.07M, up 72.88% year-over-year. In the year 2024, Crossject Société Anonyme had annual revenue of 4.12M with 6.28% growth.
Revenue (ttm)
4.07M
Revenue Growth
+72.88%
P/S Ratio
26.29
Revenue / Employee
39.54K
Employees
103
Market Cap
107.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.12M | 243.00K | 6.28% |
| Dec 31, 2023 | 3.87M | -3.19M | -45.18% |
| Dec 31, 2022 | 7.06M | 583.00K | 9.00% |
| Dec 31, 2021 | 6.48M | 1.64M | 33.77% |
| Dec 31, 2020 | 4.84M | -58.27K | -1.19% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 28.49B |
| Sanofi | 46.72B |
| Sartorius Stedim Biotech | 2.97B |
| Ipsen | 3.93B |
| Innate Pharma | 12.64M |
| MaaT Pharma | 3.92M |
| Euroapi | 852.60M |
| Adocia | 12.88M |